Provided by Tiger Trade Technology Pte. Ltd.

Cartesian Therapeutics

7.36
+0.14001.94%
Post-market: 7.360.00000.00%19:30 EDT
Volume:200.38K
Turnover:1.49M
Market Cap:222.68M
PE:-1.27
High:8.05
Open:7.32
Low:7.29
Close:7.22
52wk High:11.00
52wk Low:5.60
Shares:30.26M
Float Shares:12.40M
Volume Ratio:1.30
T/O Rate:1.62%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-5.7983
EPS(LYR):-5.0200
ROE:-7029.26%
ROA:-17.43%
PB:-1.78
PE(LYR):-1.47

Loading ...

Cartesian Therapeutics Issues Options for 121,900 Shares to Four New Employees at $7.22 Strike Price

Reuters
·
Yesterday

Cartesian Therapeutics Announces New Employment Inducement Grants

GlobeNewswire
·
Yesterday

Cartesian Therapeutics Price Target Maintained with a $40.00/Share by Needham

Dow Jones
·
Sep 30

Cartesian Therapeutics Says Descartes-08 Retreatment Cuts MG-ADL by 6.6 Points at 12 Months in Myasthenia Gravis Study

Reuters
·
Sep 29

Cartesian Therapeutics Announces Additional Retreatment Data for Descartes-08 Highlighting Deep and Durable Responses in Patients with Myasthenia Gravis

THOMSON REUTERS
·
Sep 29

Cartesian Therapeutics, - Descartes-08 Shows Mean Mg-Adl Reduction of 6.6 Points at Month 12 Post Retreatment

THOMSON REUTERS
·
Sep 29

Cartesian Therapeutics, - no New Safety Signals Reported; Safety Profile Consistent with Previous Data

THOMSON REUTERS
·
Sep 29

Cartesian Therapeutics, - Median Interval Between Initial Treatment and Retreatment Infusion is 16.6 Months

THOMSON REUTERS
·
Sep 29

Cartesian Therapeutics, Inc.: Bla Filing Expected in Mid-2027

THOMSON REUTERS
·
Sep 29

Cartesian Therapeutics, - Topline Data from Phase 3 Aurora Trial Expected in 1Q27

THOMSON REUTERS
·
Sep 29

Cartesian Therapeutics Grants New Hires Stock Options for 59,700 Shares at USD 9.27 Each

Reuters
·
Sep 08

Cartesian Therapeutics Announces New Employment Inducement Grants

GlobeNewswire
·
Sep 08

Wall Street Analysts Are Bullish on Top Healthcare Picks

TIPRANKS
·
Aug 18

Cartesian Therapeutics Price Target Maintained with a $38.00/Share by Wedbush

Dow Jones
·
Aug 18

Cantor Fitzgerald Keeps Their Buy Rating on Cartesian Therapeutics (RNAC)

TIPRANKS
·
Aug 08

Cartesian Therapeutics Grants New Hires Stock Options for 115,250 Shares Under Inducement Plan

Reuters
·
Aug 07

Cartesian Therapeutics Announces New Employment Inducement Grants

GlobeNewswire
·
Aug 07

Cartesian Therapeutics: Late-Stage Descartes-08 De-Risking and 2027 Data Wave Underpin Van Buren’s Buy Rating

TIPRANKS
·
Aug 07

Lineage Cell Therapeutics Q2 Revenue Falls but Posts Profit

Reuters
·
Aug 07

Cartesian Therapeutics, Inc. Reports Results for the Quarter Ended June 30 - Earnings Summary

Reuters
·
Aug 06